What is the evidence regarding the safety of new obesity pharmacotherapies
Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively)
Euglycemic diabetic ketoacidosis is another concern that may delay initiation or result in early discontinuation of SGLT2i therapy [4, 19]
The SURPASS-3 study was set up to investigate the efficacy and safety of tirzepatide versus a titration of the basal insulin degludec inadequately controlled by an oral therapy of T2D by metformin with or without an SGLT2 inhibitor comedication for 52 weeks (72)
Our providers will work closely with you to consider your personal health goals, discuss potential benefits and risks, manage any side effects, and emphasize the importance of continued lifestyle improvements
Like other GLP-1 class drugs, retatrutide is expected to be used as ongoing chronic treatment rather than a fixed-length course